» Articles » PMID: 36950803

NR3C2 Inhibits the Proliferation of Colorectal Cancer Via Regulating Glucose Metabolism and Phosphorylating AMPK

Overview
Journal J Cell Mol Med
Date 2023 Mar 23
PMID 36950803
Authors
Affiliations
Soon will be listed here.
Abstract

We aim to investigate the roles and mechanisms of NR3C2 in colorectal cancer (CRC). The expression of NR3C2 in CRC tumours and paired paracancerous tissues of 71 CRC patients and five CRC cell lines was detected by western blotting, immunohistochemistry and real-time reverse-transcription PCR. Moreover, NR3C2 was overexpressed or knocked down in CRC cells by lentiviral vector transfection. The proliferation of cells was measured by MTT, colony formation assay and flow cytometry. Glucose metabolism was assessed by detecting lactate production, glucose consumption and ATP production. Western blotting and real-time reverse-transcription PCR were used to detect the expression of AMPK, LDHA and HK2. The expression of NR3C2 was significantly decreased in CRC tumours compared to paracancerous tissues, which was correlated with distant metastasis, poor prognosis and advanced stages of CRC patients. Overexpressing NR3C2 suppressed the proliferation and promoted the G2/M cell cycle arrest of CRC cells. Furthermore, NR3C2 inhibited glucose metabolism by decreasing the expression of HK2 and LDHA. The phosphorylation of AMPK was also downregulated in CRC cells overexpressing NR3C2. This study demonstrated that NR3C2 inhibited the proliferation of CRC by inhibiting glucose metabolism and phosphorylation of AMPK which may serve as a therapeutic target for CRC.

Citing Articles

NR3C2 affects the proliferation and invasiveness of colon cancer cells through the Wnt/β-Catenin signaling pathway.

Nie K, He Z, Kong L J Cancer Res Clin Oncol. 2024; 150(9):411.

PMID: 39237674 PMC: 11377494. DOI: 10.1007/s00432-024-05935-8.


Co-Expression Network Analysis and Molecular Docking Demonstrate That Diosgenin Inhibits Gastric Cancer Progression via SLC1A5/mTORC1 Pathway.

Cui N, Ding F Drug Des Devel Ther. 2024; 18:3157-3173.

PMID: 39071813 PMC: 11283265. DOI: 10.2147/DDDT.S458613.


MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK-ERK and AP-1 pathways.

Yang S, Tang W, Azizian A, Gaedcke J, Ohara Y, Cawley H Carcinogenesis. 2024; 45(8):582-594.

PMID: 38629149 PMC: 11317528. DOI: 10.1093/carcin/bgae025.


Mineralocorticoid receptor signaling inhibits bladder cancer progression.

Nagata Y, Goto T, Teramoto Y, Matsukawa T, Fujimoto N, Miyamoto H Am J Cancer Res. 2024; 14(2):696-708.

PMID: 38455412 PMC: 10915320.


Network Pharmacology Analysis on the Mechanism of Xihuangwan in Treating Rectal Cancer and Radiation Enteritis.

Lv M, Ding R, Ma P, Feng Y, Zeng S, Zhang Y Curr Pharm Des. 2024; 30(9):683-701.

PMID: 38415445 DOI: 10.2174/0113816128287232240213105913.


References
1.
Kuhn E, Lombes M . The mineralocorticoid receptor: a new player controlling energy homeostasis. Horm Mol Biol Clin Investig. 2014; 15(2):59-69. DOI: 10.1515/hmbci-2013-0033. View

2.
Zhang Y, Chen Z, Li J . The current status of treatment for colorectal cancer in China: A systematic review. Medicine (Baltimore). 2017; 96(40):e8242. PMC: 5738019. DOI: 10.1097/MD.0000000000008242. View

3.
Feraco A, Marzolla V, Scuteri A, Armani A, Caprio M . Mineralocorticoid Receptors in Metabolic Syndrome: From Physiology to Disease. Trends Endocrinol Metab. 2019; 31(3):205-217. DOI: 10.1016/j.tem.2019.11.006. View

4.
Zhang Y, Li J, Wang B, Chen T, Chen Y, Ma W . LDH-A negatively regulates dMMR in colorectal cancer. Cancer Sci. 2021; 112(8):3050-3063. PMC: 8353898. DOI: 10.1111/cas.15020. View

5.
Gutierrez-Salmeron M, Garcia-Martinez J, Martinez-Useros J, Fernandez-Acenero M, Viollet B, Olivier S . Paradoxical activation of AMPK by glucose drives selective EP300 activity in colorectal cancer. PLoS Biol. 2020; 18(6):e3000732. PMC: 7326158. DOI: 10.1371/journal.pbio.3000732. View